IMI Cholesterol 1,2,3 Non-Invasive Skin Test To Debut In U.S. By Year-End
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson's McNeil Consumer & Specialty Pharmaceuticals unit is on a shortlist of potential U.S. marketing partners for International Medical Innovations' Cholesterol 1,2,3 predictive test, which is expected to launch by year-end